Oncolytics Biotech Inc. has been granted US Patent 7,049,127 entitled "Method of Producing Infectious Reovirus." The claims describe a method for producing and purifying mammalian Reovirus.

"Effective production methodologies are essential for the development of Reolysin," said Dr. Matt Coffey, chief scientific officer of Oncolytics. "This patent adds continued protection for key pieces of our growing intellectual property estate."

Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical programme includes a variety of Phase I and Phase I/II human trials using Reolysin, its proprietary formulation of the human reovirus, alone and in combination with radiation.